Drugs & Aging

, Volume 10, Issue 4, pp 249–258 | Cite as

Gastrointestinal Motility Problems in Patients with Parkinson’s Disease

Effects of Antiparkinsonian Treatment and Guidelines for Management
  • Wolfgang H. Jost
Disease Management


Gastrointestinal (GI) motility disorders are frequent in patients with Parkinson’s disease, manifesting mainly as dysphagia, disorders of gastric emptying and constipation. The most likely causes of these disorders are cerebral degeneration and degeneration of the my enteric plexus. Although the effect of antiparkinsonian medication is largely overestimated, it certainly has an influence and should be adapted accordingly in patients with GI motility disorders. In particular, anti-cholinergic drugs should be avoided, and anamnesis, clinical examination and, if necessary, diagnostic tests performed.

Domperidone, a peripheral dopamine antagonist, is the drug of choice for motility disorders of the upper GI tract, although cisapride is an alternative. In the lower GI tract, conservative therapeutic options should be used in the first instance. The administration of cisapride leads to a marked temporary improvement in symptoms in lower GI disorders, while rare forms of anism (involuntary dystonic contraction of the anal sphincter) may be treated with botulinum toxin.


  1. 1.
    Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely and Jones, 1817Google Scholar
  2. 2.
    Caplan LH, Jacobson HG, Rubinstein BM, et al. Megacolon and volvulus in Parkinson’s disease. Radiology 1965; 85: 73–8PubMedGoogle Scholar
  3. 3.
    Eadie MJ, Tyrer JH. Alimentary disorders in parkinsonism. Australas Ann Med 1965; 14: 13–22PubMedGoogle Scholar
  4. 4.
    Edwards L, Quigley EMM, Hofman R, et al. Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study. Mov Disord 1993; 8: 83–6PubMedCrossRefGoogle Scholar
  5. 5.
    Edwards LL, Quigley EMM, Harned RK, et al. Characterization of swallowing and defecation in Parkinson’s disease. Am J Gastroenterol 1994; 89: 15–25PubMedGoogle Scholar
  6. 6.
    Korczyn AD. Autonomic nervous system disturbances in Parkinson’s disease. Adv Neurol 1990; 53: 463–8PubMedGoogle Scholar
  7. 7.
    Den Hartog Jager WA. Sphingomyelin in Lewy inclusion bodies in Parkinson’s disease. Arch Neurol 1969; 21: 615–9CrossRefGoogle Scholar
  8. 8.
    Forno LS. The Lewy body in Parkinson’s disease. Adv Neurol 1986; 45: 35–43Google Scholar
  9. 9.
    Kupsky WJ, Grimes MM, Sweeting J, et al. Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987; 37: 1253–5PubMedCrossRefGoogle Scholar
  10. 10.
    Ohama E, Ikuta E Parkinson’s disease: distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol (Berl) 1976; 34: 311–9CrossRefGoogle Scholar
  11. 11.
    Qualman SJ, Haupt HM, Yang P, et al. Esophageal Lewy bodies associated with ganglion cell loss in achalasia: similarity to Parkinson’s disease. Gastroenterology 1984; 87: 848–56PubMedGoogle Scholar
  12. 12.
    Wakabayashi K, Takahashi H, Ohama E, et al. Lewy bodies in the visceral autonomic nervous system in Parkinson’s disease. Adv Neurol 1993; 60: 609–12PubMedGoogle Scholar
  13. 13.
    Edwards LL, Pfeiffer RF, Quigley EMM, et al. Gastrointestinal symptoms in Parkinson’s disease. Mov Disord 1991; 6: 151–6PubMedCrossRefGoogle Scholar
  14. 14.
    Klaue R. Parkinsonsche Krankheit (Paralysis agitans) und post-encephalitischer Parkinsonismus. Archiv fur Psychiatrie 1940; 111: 251–321CrossRefGoogle Scholar
  15. 15.
    Kuroiwa Y, Shimada Y, Toyokura Y. Postural hypotension and low R-R interval variability in parkinsonism, spino-cerebellar degeneration, and Shy-Drager syndrome. Neurology 1983; 33: 463–7PubMedCrossRefGoogle Scholar
  16. 16.
    Oppenheim H. Kleine Beiträge zur Neuropathologie. J Psychol Neurol 1902; 1: 129–46Google Scholar
  17. 17.
    Koller WC. Handbook of Parkinson’s disease. New York: Marcel Dekker Inc., 1992Google Scholar
  18. 18.
    Bateson MC, Gibberd FB, Wilson RSE. Salivary symptoms in Parkinson disease. Arch Neurol 1973; 29: 274–5PubMedCrossRefGoogle Scholar
  19. 19.
    Schwab RS, England AC. Parkinson’s disease. J Chronic Dis 1958; 8: 488–509PubMedCrossRefGoogle Scholar
  20. 20.
    Palmai G, Blackwell B. The diurnal pattern of salivary flow in normal and depressed patients. Br J Psychiatry 1965; 111: 334–8PubMedCrossRefGoogle Scholar
  21. 21.
    Parkes JD. Domperidone and Parkinson’s disease. Clin Neuro-pharmacol 1986; 9: 517–32Google Scholar
  22. 22.
    Bushmann M, Dobmeyer SM, Leeker L, et al. Swallowing abnormalities and their response to treatment in Parkinson’s disease. Neurology 1989; 39: 1309–14PubMedCrossRefGoogle Scholar
  23. 23.
    Logemann JA, Blonsky ER, Boshes B. Dysphagia in parkinsonism. JAMA 1975; 231: 69–70PubMedCrossRefGoogle Scholar
  24. 24.
    Nowack WJ, Hatelid JM, Sohn RS. Dysphagia in parkinsonism [letter]. Arch Neurol 1977; 34: 320PubMedCrossRefGoogle Scholar
  25. 25.
    Fischer RA, Ellison GW, Thayer WR, et al. Esophageal motility in neuromuscular disorders. Ann Intern Med 1965; 63: 229–48PubMedGoogle Scholar
  26. 26.
    Calne DB, Shaw DG, Spiers ASD, et al. Swallowing in parkinsonism. Br J Radiol 1970; 43: 456–7PubMedCrossRefGoogle Scholar
  27. 27.
    Eadie MJ, Tyrer JH. Radiological abnormalities of the upper part of the alimentary tract in parkinsonism. Australas Ann Med 1965; 14: 23–7PubMedGoogle Scholar
  28. 28.
    Palmer ED. Dysphagia in parkinsonism [editorial]. JAMA 1974; 229: 1349PubMedCrossRefGoogle Scholar
  29. 29.
    Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969; 280: 337–45PubMedCrossRefGoogle Scholar
  30. 30.
    Bramble MG, Cunliffe J, Dellipiani AW. Evidence for a change in neurotransmitter affecting oesophageal motility in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1978; 41: 709–12PubMedCrossRefGoogle Scholar
  31. 31.
    Kempster PA, Lees AJ, Crichton P, et al. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson’s disease and its treatment with apomorphine. Mov Disord 1989; 4: 47–52PubMedCrossRefGoogle Scholar
  32. 32.
    Lieberman AN, Horowitz L, Redmond P, et al. Dysphagia in Parkinson’s disease. Am J Gastroenterol 1980; 74: 157–60PubMedGoogle Scholar
  33. 33.
    Gibberd FB, Gleeson JA, Gossage AAR, et al. Oesophageal dilatation in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1974; 37: 938–40PubMedCrossRefGoogle Scholar
  34. 34.
    Jost WH, Schimrigk K. Cisapride treatment of constipation in Parkinson’s disease. Mov Disord 1993; 8: 339–43PubMedCrossRefGoogle Scholar
  35. 35.
    Kaneoke Y, Koike Y, Sakurai N, et al. Gastrointestinal dysfunction in Parkinson’s disease detected by electrogastroenter-ography. J Auton Nerv Syst 1995; 50: 275–81PubMedCrossRefGoogle Scholar
  36. 36.
    Djaldetti R, Baron J, Ziv I, et al. Gastric emptying in Parkinson’s disease: patients with and without response fluctuations. Neurology 1996; 46: 1051–4PubMedCrossRefGoogle Scholar
  37. 37.
    Kurlan R, Rubin AJ, Miller C, et al. Continuous intraduodenal infusion of levodopa for resistant on-off fluctuations in parkinsonism [abstract]. Ann Neurol 1985; 18: 139Google Scholar
  38. 38.
    Champion MC. Domperidone. Gen Pharmacol 1988; 19: 499–505PubMedCrossRefGoogle Scholar
  39. 39.
    Mearrick PT, Wade DN, Birkett DJ, et al. Metoclopramide, gastric emptying and L-dopa absorption. Aust N Z J Med 1974; 4: 144–8PubMedCrossRefGoogle Scholar
  40. 40.
    Wade DN, Mearrick PT, Birkett DT, et al. Variability of L-dopa absorption in man. Aust N Z J Med 1974; 4: 138–43PubMedCrossRefGoogle Scholar
  41. 41.
    Rivera-Calimlim L, Dujovne CA, Morgan JP, et al. L-dopa treatment failure: explanation and correction. BMJ 1970; 4: 93–4PubMedCrossRefGoogle Scholar
  42. 42.
    Indo T, Ando K. Metoclopramide-induced parkinsonism. Arch Neurol 1982; 39: 494–6PubMedCrossRefGoogle Scholar
  43. 43.
    Paulseth JE, Jensen JJJ, Klawans HL. Domperidone therapy in patients with Parkinson’s disease with levodopa-carbidopa-related gastrointestinal complaints. Ann Neurol 1984; 16: 127–8Google Scholar
  44. 44.
    Eadie MJ. Gastric secretion in parkinsonism. Australas Ann Med 1963; 12: 346–50PubMedGoogle Scholar
  45. 45.
    Bingham JR, Ingelfinger FJ, Smithwick RH. The effects of sympathectomy on the motility of the human gastrointestinal and biliary tracts. Gastroenterology 1950; 15: 6–17PubMedGoogle Scholar
  46. 46.
    Lewitan A, Nathanson L, Slade WR. Megacolon and dilatation of the small bowel in parkinsonism. Gastroenterology 1951; 17: 367–74PubMedGoogle Scholar
  47. 47.
    Calne DB, Brennan J, Spiers ASD, et al. Hypotension caused by L-dopa. BMJ 1970; I: 474–5CrossRefGoogle Scholar
  48. 48.
    Jost WH, Schimrigk K. Constipation in Parkinson’s disease. Klin Wochenschr 1991; 69: 906–9PubMedCrossRefGoogle Scholar
  49. 49.
    Mesec A, Sega S, Kiauta T. The influence of the type, duration, severity and levodopa treatment of Parkinson’s disease on cardiovascular autonomic responses. Clin Auton Res 1993; 3: 339–44PubMedCrossRefGoogle Scholar
  50. 50.
    Turkka JT, Juujärvi KK, Lapinlampi TO, et al. Serum noradren-aline response to standing up in patients with Parkinson’s disease. Eur Neurol 1986; 25: 355–61PubMedCrossRefGoogle Scholar
  51. 51.
    Wang SJ, Fuh JL, Shan DE, et al. Sympathetic skin response and R-R interval variation in Parkinson’s disease. Mov Disord 1993; 8: 151–7PubMedCrossRefGoogle Scholar
  52. 52.
    Pallis CA. Parkinsonism: natural history and clinical features. BMJ 1971; 3: 683–90PubMedCrossRefGoogle Scholar
  53. 53.
    Singer C, Weiner WJ, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson’s disease. Eur Neurol 1992; 32: 134–40PubMedCrossRefGoogle Scholar
  54. 54.
    Kuroiwa Y, Wada T, Tohgi H. Measurement of blood pressure and heart-rate variation while resting supine and standing for the evaluation of autonomic dysfunction. J Neurol 1987; 235: 65–8PubMedCrossRefGoogle Scholar
  55. 55.
    Porter RW, Bors E. Neurogenic bladder in parkinsonism: effect of thalamotomy. J Neurosurg 1971; 34: 27–32PubMedCrossRefGoogle Scholar
  56. 56.
    Jost WH, Schimrigk K. Bestimmung der Kolontransitzeit beim Parkinson - Syndrom. Aktuelle Neurol 1992; 19: 52–3CrossRefGoogle Scholar
  57. 57.
    Neundörfer B. Risiken und Nebenwirkungen der medikamentösen Therapie. Nervenheilkunde 1992; 11: 63–7Google Scholar
  58. 58.
    Siegmund H. Anatomisch nachgewiesene Folgen von Tonus-und Motilitätsstörungen des Verdauungskanals bei Enzepha-litikern, die mit Atropin behandelt wurden. MMW Munch Med Wochenschr 1935; 82: 453–4Google Scholar
  59. 59.
    Jost WH, Jung G, Schimrigk K. Colonic transit in non-idiopathic Parkinson’s syndrome. Eur Neurol 1994; 34: 329–31PubMedCrossRefGoogle Scholar
  60. 60.
    Herrn F, Jordan E, Jost WH, et al. Colontransitzeit bei neuromus-kulären Erkrankungen vor und nach Colonreflexmassagen [abstract]. Med Klin 1995; 90: 199Google Scholar
  61. 61.
    Den Hartog Jager WA, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous system in idio-pathic paralysis agitans. J Neurol Neurosurg Psychiatry 1960; 23: 283–90PubMedCrossRefGoogle Scholar
  62. 62.
    Eadie MJ. The pathology of certain medullary nuclei in parkinsonism. Brain 1963; 86: 781–92PubMedCrossRefGoogle Scholar
  63. 63.
    Oyanagi K, Wakabayashi K, Ohama E, et al. Lewy bodies in the lower sacral parasympathetic neurons of a patient with Parkinson’s disease. Acta Neuropathol 1990; 80: 558–9PubMedCrossRefGoogle Scholar
  64. 64.
    Singaram C, Ashraf W, Quigley EMM, et al. Enteric nervous system (ENS) dopamine depletion in Parkinson’s disease (PD) [abstract]. Mov Disord 1994; 9 Suppl. 1: 100Google Scholar
  65. 65.
    Wakabayashi K, Takahashi H, Takeda S, et al. Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathol 1988; 76: 217–21PubMedCrossRefGoogle Scholar
  66. 66.
    Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson’s disease. Arch Neurol 1989; 46: 1061–4PubMedCrossRefGoogle Scholar
  67. 67.
    Ashraf W, Pfeiffer RF, Quigley EMM. Anorectal manometry in the assessment of anorectal function in Parkinson’s disease: a comparison with chronic idiopathic constipation. Mov Disord 1994; 9: 655–63PubMedCrossRefGoogle Scholar
  68. 68.
    Jost WH, Raulf F, Schimrigk K. Anismus: Definition, Patho-physiologie, Diagnose und Therapie. Kontinenz 1994; 3: 211–5Google Scholar
  69. 69.
    Mathers SE, Kempster PA, Swash M, et al. Constipation and paradoxical puborectalis contraction in anismus and Parkinson’s disease: a dystonic phenomenon?. J Neurol Neurosurg Psychiatry 1988; 51: 1503–7PubMedCrossRefGoogle Scholar
  70. 70.
    Reboa G, Arnulfo G, Frascio M, et al. Colon motility and colo-anal reflexes in chronic idiopathic constipation. Eur J Clin Pharmacol 1984; 26: 745–8PubMedCrossRefGoogle Scholar
  71. 71.
    Djaldetti R, Koren M, Achiron A, et al. Effect of cisapride on response fluctuations in Parkinson’s disease. Mov Disord 1995; 10: 81–4PubMedCrossRefGoogle Scholar
  72. 72.
    Neira WD, Sanchez V, Mena MA, et al. The effects of cisapride on plasma L-dopa levels and response in Parkinson’s disease. Mov Disord 1995; 10: 66–70PubMedCrossRefGoogle Scholar
  73. 73.
    Jost WH, Schimrigk K. Long-term results with cisapride in Parkinson’s disease. Mov Disord. In pressGoogle Scholar
  74. 74.
    Jost WH, Schimrigk K. Elektromyogramm des M. sphincter ani externus beim idiopathischen Parkinson Syndrom. Aktuelle Neurol 1996; 23: 167–70CrossRefGoogle Scholar
  75. 75.
    Wenning GK, Quinn N. Multisytematrophie. Aktuelle Neurol 1994; 21: 120–6CrossRefGoogle Scholar
  76. 76.
    Jost WH. Neurologie des Beckenbodens. London: Chapman & Hall, 1997Google Scholar
  77. 77.
    Lewy FH. Zur pathologischen Anatomie der Paralysis agitans. Dtsch Z Nervenheilkd 1913; 50: 50–5Google Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Wolfgang H. Jost
    • 1
  1. 1.Department of NeurologyGerman Diagnostic ClinicWiesbadenGermany

Personalised recommendations